Servier signed a definitive agreement to acquire 100% of Symphogen, a Danish therapeutic antibody discovery company, to boost its antibody capabilities and leverage Symphogen's R&D pipeline. The deal advanced Servier's strategic ambition to become a recognized oncology player. Symphogen became Servier's antibody center of excellence, retaining its Ballerup, Denmark HQ and operating as a standalone entity. Terms not disclosed.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Pipeline outcome
Mixed
Assessment window: 5yr post-close.
Key facts
AnnouncedApr 03, 2020
ClosedJun 01, 2020
Deal typeAcquisition/Merger
Therapeutic areaOncology and immuno-oncology
IndicationsOncology and immuno-oncology
Key assetsSymphogen oncology and immuno-oncology antibody pipeline; antibody discovery platform
MechanismTherapeutic antibody discovery and development